{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T00:33:35Z","timestamp":1794789215856,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203167"],"award-info":[{"award-number":["82203167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460722"],"award-info":[{"award-number":["82460722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"gansu provincial health industry science and technology innovation project","award":["GSWSQNPY2024-12"],"award-info":[{"award-number":["GSWSQNPY2024-12"]}]},{"name":"cuiying scientific and technological innovation program of lanzhou university second hospital","award":["CY2022-MS-A09"],"award-info":[{"award-number":["CY2022-MS-A09"]}]},{"name":"cuiying scientific and technological innovation program of lanzhou university second hospital","award":["CY2023-MS-A05"],"award-info":[{"award-number":["CY2023-MS-A05"]}]},{"name":"traditional chinese medicine scientific research project of gansu province, china","award":["GZKP2023-36"],"award-info":[{"award-number":["GZKP2023-36"]}]},{"name":"cuiying scientific training program for undergraduates of lanzhou university","award":["CYXZ2024-11"],"award-info":[{"award-number":["CYXZ2024-11"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Prostate cancer is a major global health challenge, characterized by high morbidity and mortality rates. Traditional treatment options, including androgen deprivation therapy and chemotherapy, often lead to drug resistance. In recent years, natural compounds have garnered attention for their potential therapeutic effects. Evodiamine, a bioactive alkaloid from Evodia rutaecarpa, has demonstrated promising anti-cancer properties in various malignancies, including oral squamous cell carcinoma, breast, colorectal, and ovarian cancers. This study explores the efficacy of evodiamine in prostate cancer cells and investigates the mechanisms underlying evodiamine-induced cell death.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>To investigate the effects of evodiamine on prostate cancer cells, various cell lines, including both castration-sensitive and castration-resistant variants, were treated with different concentrations of evodiamine for various durations. Cell viability, proliferation, invasion ability, and colony formation were assessed using the CCK8 assay, EdU assay, 3D matrigel drop invasion assay, and colony formation assay, respectively. The effects of evodiamine on apoptosis were analyzed using FACS, Hoechst staining, and Western blot. To evaluate its effects on ferroptosis, malondialdehyde (MDA) and glutathione (GSH) assay kits, as well as DCFH-DA and the lipid peroxidation sensor BODIPY<jats:sup>\u2122<\/jats:sup> 581\/501 C11 fluorescent probes, were employed. The molecular mechanisms through which evodiamine regulates GPX4 protein instability were investigated using Western blot and TRIM26 ectopic expression. Additionally, a mouse xenograft model derived from DU145 cells was established to evaluate the in vivo effects of evodiamine and its molecular mechanisms, utilizing hematoxylin and eosin (H&amp;E) staining, immunohistochemistry (IHC), and Western blot analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Evodiamine significantly suppressed cell viability, proliferation, invasion, and colony formation in prostate cancer cells. Importantly, evodiamine-induced cell death in the PC3 and DU145 cell lines was independent of apoptosis pathway. Instead, evodiamine increased reactive oxygen species (ROS) production, lipid ROS levels and MDA levels, while decreasing GSH levels, indicating the induction of ferroptosis. The key role of ROS in evodiamine-induced ferroptosis was further confirmed by the partial reversal of cell death upon treatment with the ROS scavenger N-acetylcysteine (NAC). Mechanistically, evodiamine induced ferroptosis by destabilizing GPX4 protein in a TRIM26-dependent manner. Moreover, in vivo studies demonstrated that evodiamine significantly inhibited tumor growth and induced ferroptosis in tumor cells, highlighting its therapeutic potential.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study demonstrates that evodiamine exerts potent antitumor effects against prostate cancer through inhibiting TRIM26-mediated stabilization of GPX4 protein and triggering ferroptosis. These findings suggest that evodiamine, a natural product derived from traditional Chinese medicine, could be a promising therapeutic agent for prostate cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s13020-025-01130-0","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T08:15:37Z","timestamp":1748247337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evodiamine induces ferroptosis in prostate cancer cells by inhibiting TRIM26-mediated stabilization of GPX4"],"prefix":"10.1186","volume":"20","author":[{"given":"Lanlan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9254-5339","authenticated-orcid":false,"given":"Shanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"3","key":"1130_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinic. 2024;74(3):229\u201363.","journal-title":"CA A Cancer J Clinic"},{"issue":"1","key":"1130_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA A Cancer Clinic. 2024;74(1):12\u201349.","journal-title":"CA A Cancer Clinic"},{"issue":"14","key":"1130_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/pros.24768","volume":"84","author":"AK Miyahira","year":"2024","unstructured":"Miyahira AK, Soule HR. The 30th annual prostate cancer foundation scientific retreat report. Prostate. 2024;84(14):1271\u201389.","journal-title":"Prostate"},{"key":"1130_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216706","volume":"586","author":"P Kaur","year":"2024","unstructured":"Kaur P, Shankar E, Gupta S. EZH2-mediated development of therapeutic resistance in cancer. Cancer Lett. 2024;586: 216706.","journal-title":"Cancer Lett"},{"issue":"22","key":"1130_CR5","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41388-024-03036-x","volume":"43","author":"C Rawat","year":"2024","unstructured":"Rawat C, Heemers HV. Alternative splicing in prostate cancer progression and therapeutic resistance. Oncogene. 2024;43(22):1655\u201368.","journal-title":"Oncogene"},{"issue":"1","key":"1130_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12894-022-01020-9","volume":"22","author":"Y Tao","year":"2022","unstructured":"Tao Y, Liu S, Lu J, Fu S, Li L, Zhang J, et al. FOXO3a-ROS pathway is involved in androgen-induced proliferation of prostate cancer cell. BMC Urol. 2022;22(1):70.","journal-title":"BMC Urol"},{"issue":"14","key":"1130_CR7","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1016\/j.cell.2022.06.003","volume":"185","author":"BR Stockwell","year":"2022","unstructured":"Stockwell BR. Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications. Cell. 2022;185(14):2401\u201321.","journal-title":"Cell"},{"issue":"4","key":"1130_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1130_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114741","volume":"192","author":"M Li","year":"2021","unstructured":"Li M, Chen X, Wang X, Wei X, Wang D, Liu X, et al. RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction. Biochem Pharmacol. 2021;192: 114741.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"1130_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani A, Hsu EC, Aslan M, Rice MA, Nguyen HM, Brooks JD, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Can Res. 2021;81(6):1583\u201394.","journal-title":"Can Res"},{"issue":"1","key":"1130_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13020-024-00881-6","volume":"19","author":"S Liu","year":"2024","unstructured":"Liu S, Tao Y, Wu S, Lin J, Fu S, Lu J, et al. Sanguinarine chloride induces ferroptosis by regulating ROS\/BACH1\/HMOX1 signaling pathway in prostate cancer. Chinese medicine. 2024;19(1):7.","journal-title":"Chinese medicine"},{"key":"1130_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176007","volume":"957","author":"Y Yu","year":"2023","unstructured":"Yu Y, Huang X, Liang C, Zhang P. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer. Eur J Pharmacol. 2023;957: 176007.","journal-title":"Eur J Pharmacol"},{"key":"1130_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25061320","author":"ST Hwang","year":"2020","unstructured":"Hwang ST, Um JY, Chinnathambi A, Alharbi SA, Narula AS, Namjoshi OA, et al. Evodiamine mitigates cellular growth and promotes apoptosis by targeting the c-Met pathway in prostate cancer cells. Molecules. 2020. https:\/\/doi.org\/10.3390\/molecules25061320.","journal-title":"Molecules"},{"issue":"1","key":"1130_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12906-023-04254-8","volume":"23","author":"Y Lu","year":"2023","unstructured":"Lu Y, Dong K, Yang M, Liu J. Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer. BMC Complement Med Therap. 2023;23(1):433.","journal-title":"BMC Complement Med Therap"},{"key":"1130_CR15","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128356225250305081937","author":"MI Hasan","year":"2025","unstructured":"Hasan MI, Islam KM, Hasan MN, Rahman MM, Rahman MH, Moon S, et al. Exploring the therapeutic potential of evodia rutaecarpa in early-onset pancreatic cancer: a network pharmacology and molecular docking approach. Curr Pharmaceut Des. 2025. https:\/\/doi.org\/10.2174\/0113816128356225250305081937.","journal-title":"Curr Pharmaceut Des"},{"issue":"4","key":"1130_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/kjm2.12803","volume":"40","author":"LQ Lin","year":"2024","unstructured":"Lin LQ, Lv SY, Ren HZ, Li RR, Li L, Pang YQ, et al. Evodiamine inhibits EPRS expression to regulate glutamate metabolism and proliferation of oral squamous cell carcinoma cells. Kaohsiung J Med Sci. 2024;40(4):348\u201359.","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"1130_CR17","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.1080\/21655979.2021.1972082","volume":"12","author":"L Ren","year":"2021","unstructured":"Ren L, Lou Y, Sun M. The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) \/ receptor for advanced glycation end products (RAGE) pathway. Bioengineered. 2021;12(1):5985\u201395.","journal-title":"Bioengineered"},{"issue":"1","key":"1130_CR18","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1038\/s41598-024-51970-3","volume":"14","author":"R Solanki","year":"2024","unstructured":"Solanki R, Rajput PK, Jodha B, Yadav UCS, Patel S. Enhancing apoptosis-mediated anticancer activity of evodiamine through protein-based nanoparticles in breast cancer cells. Sci Rep. 2024;14(1):2595.","journal-title":"Sci Rep"},{"issue":"63","key":"1130_CR19","doi-asserted-by":"publisher","first-page":"37067","DOI":"10.1039\/C9RA07096F","volume":"9","author":"X Tan","year":"2019","unstructured":"Tan X, Zhou Y, Shen L, Jia H, Tan X. A mitochondria-targeted delivery system of doxorubicin and evodiamine for the treatment of metastatic breast cancer. RSC Adv. 2019;9(63):37067\u201378.","journal-title":"RSC Adv"},{"issue":"8","key":"1130_CR20","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.7150\/jca.92087","volume":"15","author":"Q Zheng","year":"2024","unstructured":"Zheng Q, Jing S, Hu L, Meng X. Evodiamine inhibits colorectal cancer growth via RTKs mediated PI3K\/AKT\/p53 signaling pathway. J Cancer. 2024;15(8):2361\u201372.","journal-title":"J Cancer"},{"issue":"3","key":"1130_CR21","first-page":"353","volume":"36","author":"L Wei","year":"2016","unstructured":"Wei L, Jin X, Cao Z, Li W. Evodiamine induces extrinsic and intrinsic apoptosis of ovarian cancer cells via the mitogen-activated protein kinase\/phosphatidylinositol-3-kinase\/protein kinase B signaling pathways. J Tradit Chinese Med Chung i tsa chih ying wen pan. 2016;36(3):353\u20139.","journal-title":"J Tradit Chinese Med Chung i tsa chih ying wen pan"},{"key":"1130_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154493","volume":"108","author":"L Zhang","year":"2023","unstructured":"Zhang L, Li L, Chen X, Yuan S, Xu T, Zhao W, et al. Evodiamine inhibits ESCC by inducing M-phase cell-cycle arrest via CUL4A\/p53\/p21 axis and activating noxa-dependent intrinsic and DR4-dependent extrinsic apoptosis. Phytomedicine. 2023;108: 154493.","journal-title":"Phytomedicine"},{"issue":"2","key":"1130_CR23","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3390\/ijms15023154","volume":"15","author":"T Zhang","year":"2014","unstructured":"Zhang T, Qu S, Shi Q, He D, Jin X. Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR\/S6K1-mediated downregulation of Mcl-1. Int J Mol Sci. 2014;15(2):3154\u201371.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1130_CR24","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.3390\/ijms24076021","volume":"24","author":"CY Hu","year":"2023","unstructured":"Hu CY, Wu HT, Shan YS, Wang CT, Shieh GS, Wu CL, et al. Evodiamine exhibits anti-bladder cancer activity by suppression of glutathione peroxidase 4 and induction of ferroptosis. Int J Mol Sci. 2023;24(7):6021.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1130_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12885-025-13522-4","volume":"25","author":"KP Li","year":"2025","unstructured":"Li KP, Wan S, Wang CY, Chen SY, Wang L, Liu SH, et al. Multi-omics analysis reveals the impact of YAP\/TEAD4-mediated EIF5A1 expression on mitochondrial apoptosis and bladder cancer progression. BMC Cancer. 2025;25(1):234.","journal-title":"BMC Cancer"},{"issue":"7784","key":"1130_CR26","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688\u201392.","journal-title":"Nature"},{"issue":"7784","key":"1130_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693\u20138.","journal-title":"Nature"},{"key":"1130_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3389\/fonc.2020.00949","volume":"10","author":"L Yang","year":"2020","unstructured":"Yang L, Chen X, Yang Q, Chen J, Huang Q, Yao L, et al. Broad spectrum deubiquitinase inhibition induces both apoptosis and ferroptosis in cancer cells. Front Oncol. 2020;10:949.","journal-title":"Front Oncol"},{"issue":"2","key":"1130_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41388-022-02537-x","volume":"42","author":"D Li","year":"2023","unstructured":"Li D, Wang Y, Dong C, Chen T, Dong A, Ren J, et al. CST1 inhibits ferroptosis and promotes gastric cancer metastasis by regulating GPX4 protein stability via OTUB1. Oncogene. 2023;42(2):83\u201398.","journal-title":"Oncogene"},{"issue":"10","key":"1130_CR30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41419-023-06222-z","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Xia Y, Wang Y, Zhu R, Li H, Liu Y, et al. The E3 ligase TRIM26 suppresses ferroptosis through catalyzing K63-linked ubiquitination of GPX4 in glioma. Cell Death Dis. 2023;14(10):695.","journal-title":"Cell Death Dis"},{"issue":"5","key":"1130_CR31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41556-023-01133-9","volume":"25","author":"K Wu","year":"2023","unstructured":"Wu K, Yan M, Liu T, Wang Z, Duan Y, Xia Y, et al. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function. Nat Cell Biol. 2023;25(5):714\u201325.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"1130_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update part i: screening, diagnosis, and local treatment with curative intent. Euro Urol. 2024;86(2):148\u201363.","journal-title":"Euro Urol"},{"issue":"10","key":"1130_CR33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.trecan.2023.06.009","volume":"9","author":"G Gebrael","year":"2023","unstructured":"Gebrael G, Fortuna GG, Sayegh N, Swami U, Agarwal N. Advances in the treatment of metastatic prostate cancer. Trends Cancer. 2023;9(10):840\u201354.","journal-title":"Trends Cancer"},{"issue":"10305","key":"1130_CR34","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021;398(10305):1075\u201390.","journal-title":"Lancet"},{"issue":"10","key":"1130_CR35","doi-asserted-by":"publisher","first-page":"16711","DOI":"10.1002\/jcb.28929","volume":"120","author":"A Abazid","year":"2019","unstructured":"Abazid A, Martin B, Choinowski A, McNeill RV, Brandenburg LO, Ziegler P, et al. The androgen receptor antagonist enzalutamide induces apoptosis, dysregulates the heat shock protein system, and diminishes the androgen receptor and estrogen receptor beta1 expression in prostate cancer cells. J Cell Biochem. 2019;120(10):16711\u201322.","journal-title":"J Cell Biochem"},{"issue":"2","key":"1130_CR36","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3892\/ijo.2015.3274","volume":"48","author":"H Grossebrummel","year":"2016","unstructured":"Grossebrummel H, Peter T, Mandelkow R, Weiss M, Muzzio D, Zimmermann U, et al. Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. Int J Oncol. 2016;48(2):793\u2013800.","journal-title":"Int J Oncol"},{"key":"1130_CR37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12935-019-1021-9","volume":"19","author":"J Han","year":"2019","unstructured":"Han J, Zhang J, Zhang W, Zhang D, Li Y, Zhang J, et al. Abiraterone and MDV3100 inhibits the proliferation and promotes the apoptosis of prostate cancer cells through mitophagy. Cancer Cell Int. 2019;19:332.","journal-title":"Cancer Cell Int"},{"key":"1130_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1476-4598-8-68","volume":"8","author":"M Melanie","year":"2009","unstructured":"Melanie M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, et al. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF\/p75. Mol Cancer. 2009;8:68.","journal-title":"Mol Cancer"},{"issue":"5","key":"1130_CR39","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.3892\/mmr.2016.5000","volume":"13","author":"P Xiao","year":"2016","unstructured":"Xiao P, Ma T, Zhou C, Xu Y, Liu Y, Zhang H. Anticancer effect of docetaxel induces apoptosis of prostate cancer via the cofilin-1 and paxillin signaling pathway. Mol Med Rep. 2016;13(5):4079\u201384.","journal-title":"Mol Med Rep"},{"issue":"12","key":"1130_CR40","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1038\/sj.onc.1207326","volume":"23","author":"H Huang","year":"2004","unstructured":"Huang H, Zegarra-Moro OL, Benson D, Tindall DJ. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells. Oncogene. 2004;23(12):2161\u201376.","journal-title":"Oncogene"},{"issue":"5","key":"1130_CR41","first-page":"1567","volume":"148","author":"M Krajewska","year":"1996","unstructured":"Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996;148(5):1567\u201376.","journal-title":"Am J Pathol"},{"issue":"8","key":"1130_CR42","doi-asserted-by":"publisher","first-page":"6105","DOI":"10.18632\/oncotarget.3368","volume":"6","author":"FR Santer","year":"2015","unstructured":"Santer FR, Erb HH, Oh SJ, Handle F, Feiersinger GE, Luef B, et al. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy. Oncotarget. 2015;6(8):6105\u201322.","journal-title":"Oncotarget"},{"key":"1130_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2022.100916","volume":"66","author":"Y Wang","year":"2023","unstructured":"Wang Y, Wu X, Ren Z, Li Y, Zou W, Chen J, et al. Overcoming cancer chemotherapy resistance by the induction of ferroptosis. Drug Resist Updates. 2023;66: 100916.","journal-title":"Drug Resist Updates"},{"issue":"1","key":"1130_CR44","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47.","journal-title":"Mol Cancer"},{"issue":"2","key":"1130_CR45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12020-021-02907-7","volume":"75","author":"P Cheng","year":"2022","unstructured":"Cheng P, Zhang X, Wang X, Liu C, Zhao X, Fan J, et al. Identification of evodiamine as a suppressor of prostate cancer progression by reducing AR transcriptional activity via targeting Src. Endocrine. 2022;75(2):635\u201345.","journal-title":"Endocrine"},{"key":"1130_CR46","doi-asserted-by":"publisher","first-page":"4399334","DOI":"10.1155\/2022\/4399334","volume":"2022","author":"Y Lei","year":"2022","unstructured":"Lei Y, Chan M, Liu H, Lyu W, Chen L, Zhong Y, et al. Evodiamine as the active compound of evodiae fructus to inhibit proliferation and migration of prostate cancer through PI3K\/AKT\/NF-kappaB signaling pathway. Dis Markers. 2022;2022:4399334.","journal-title":"Dis Markers"},{"issue":"5","key":"1130_CR47","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01130-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01130-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T09:03:49Z","timestamp":1748250229000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-025-01130-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1130"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01130-0","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this study, all animal experiment and procedures have been approved and performed in accordance with the Animal Care Welfare Committee of Lanzhou University Second Hospital Ethics approval and consent to participate (D2024-011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}